← board
KLRS
distress 5/10 · elevated risk$3.97-2%today-64% from 52w high
Lead: nAMD
Revenue
pre-revenue
Liquidity
$105M
Runway
2.5 yrs
Shares 1y
+27%
Price & events
-59.4% over 6M
CatalystRating changeDilutionFinancingdashed = today
-2.5%
1D
-13.9%
1W
-11.2%
1M
-34.9%
3M
-59.5%
6M
+43.3%
1Y
-77.7%
2Y
-99.1%
5Y
-99.6%
All
Overview
- Market Cap
- $94.46M
- Volume
- 6.38K
- 52 Week Range
- $2.27 – $10.98
- Total Shares
- 23.79M
- Float Shares
- 7.22M
- Short %
- 6.04%
- % Held by Insiders
- 8.81%
- % Held by Institutions
- 77.88%
- RVOL
- 0.01x
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 4
- first half of 2027readoutPhase 1/2TH103 · Initial data from Phase 1b/2 standard four-dose loading regimen in treatment-naïve nAMD patientsSEC 8-K
- second half of 2026Guided 55%readoutPhase 1/2TH103 · Preliminary efficacy and safety data from Phase 1b/2 MAD studySEC 8-K
- December 17, 2025 at 4:30 pm ESTconferencedata presentationsecondaryTH103 · Virtual investor event to discuss initial Phase 1a dataSEC 8-K
- 2024-11-07partnershipMerger agreement with Kalaris Therapeutics; pre-merger Kalaris stockholders to own ~74.95% of combined company.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $19 (+371% upside) · 7 analysts
- 2026-06-15TD CowenBuy
- 2026-05-14WedbushOutperform
- 2026-05-13CitizensMarket Outperform
- 2026-04-16Morgan StanleyOverweight
- 2025-12-23Chardan CapitalBuy
- 2025-11-03CitizensMarket Outperform
Competitors — nAMD
Recent news
- 2026-07-22Kalaris appoints Liisa Bayko as CFO - MSN
- 2026-07-22Why is Kalaris Therapeutics stock gaining Friday? - MSN
- 2026-07-22Kalaris Therapeutics Appoints Liisa Bayko as New Chief Financial Officer - VisionMonday.com
- 2026-07-21Kalaris Therapeutics Inc. (KLRS) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
- 2026-07-21Kalaris Therapeutics files Form 3 for CFO Liisa Ann Bayko - Bitget
- 2026-07-20Kalaris Therapeutics appoints Liisa Bayko as CFO - Investing.com
- 2026-07-20Kalaris Therapeutics stock falls despite naming new CFO - Investing.com
- 2026-07-20Kalaris Therapeutics, Inc. Announces Appointment of Liisa Bayko to Chief Financial Officer, Effective July 20, 2026 - marketscreener.com
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.